The science
The evidence base for this product is unusually direct, because both headline actives have randomized trial data at nearby doses. The bakuchiol study that started the category was a 2019 prospective, randomized, double-blind trial in the British Journal of Dermatology in which 0.5 percent bakuchiol applied twice daily was compared with 0.5 percent retinol applied nightly over twelve weeks: both significantly reduced wrinkle surface area and hyperpigmentation with no statistical difference between them, while the retinol group reported more facial scaling and stinging. The molecular rationale came earlier, in a 2014 International Journal of Cosmetic Science paper that used gene expression profiling to show bakuchiol modulates many of the same retinoid-responsive genes as retinol despite no structural resemblance, and demonstrated clinical anti-aging effects. Paula's Choice's 2 percent is four times the trial dose; there is no trial at that concentration, so the extrapolation is that more bakuchiol adds more retinoid-like signalling, which is plausible but unproven.
The retinol side has its own support. A 2020 clinically controlled trial in Skin Pharmacology and Physiology compared 0.3 and 0.5 percent retinol serums over twelve weeks and found both significantly improved wrinkles and skin biomechanics, with 0.3 percent already producing meaningful change and better tolerability — the concentration this product uses. The combination of 0.3 percent retinol and 2 percent bakuchiol has not been tested together, so the product's claim to be more than the sum of its parts rests on mechanism: two agents acting on overlapping retinoid pathways, with bakuchiol's documented anti-inflammatory activity offsetting retinol's irritation.
The supporting cast is conventional and sensible. Licorice-derived glycyrrhizate, oat kernel extract and allantoin are well-characterised anti-irritants; ceramide NG, hyaluronate and soy sterols address the barrier disruption that accelerated turnover causes; the four peptides have small manufacturer-sponsored studies behind their firming claims; and tetrahexyldecyl ascorbate ahead of the retinol likely serves as much to stabilise the vitamin A as to brighten. Nothing in the tail changes the core reading: this is a mid-dose retinoid with credible trial support for each of its two actives and a well-built tolerability wrapper.
References 3 ShowHide
- Prospective, randomized, double-blind assessment of topical bakuchiol and retinol for facial photoageing — British Journal of Dermatology (2019)
- Bakuchiol: a retinol-like functional compound revealed by gene expression profiling and clinically proven to have anti-aging effects — International Journal of Cosmetic Science (2014)
- A Clinical Anti-Ageing Comparative Study of 0.3 and 0.5% Retinol Serums: A Clinically Controlled Trial — Skin Pharmacology and Physiology (2020)